[299] BALANCING BLOOD GLUCOSE LEVELS USING GUT MICROBIOME

Lihi Segal[1], [1] Daytwo

- **Investment Rational:** DayTwo balances blood sugar levels using personally tailored food recommendations based on the gut microbiome. Adults aged 45-64 are the most diagnosed age group for diabetes and other metabolic disorders, but generalized dietary guidelines induce high blood sugar responses in many cases. Our technology is based on research led by Prof. Eran Segal and Dr. Eran Elinav from the Weizmann Institute.

- **Business Strategy** DayTwo offers a B2C cloud-based application that provides real-time scoring of food, for balancing blood sugar levels. DayTwo will also serve as a B2B platform for companies providing value related to nutrition and microbiome, allowing them to access the personalized nutrition and microbiome profiles of their users through an API. The application will have a one-time fee plus a recurring fee.

- **Core Technology** People respond very differently to the same food. Despite the variability, people get generalized dietary guidelines, that may induce high blood sugar responses in many cases. DayTwo's proprietary, patent pending, machine learning algorithms integrates personal parameters and microbiome features to accurately predict the personalized post-meal glucose response to arbitrary meals.

- **Product Profile/Pipeline** DayTwo's application targets the diabetic and pre-diabetic individuals, and sold both directly to consumers and via partners, allowing them access to users' Personalized Nutrition engine and Microbiome data. Partners will be HealthPlans and Employers offering Diabetes Management Programs, doctors and nutritionists helping patients manage blood sugar levels.

What's Next? The product is launched in Israel and the US. DayTwo will continue to collaborate with Prof. Eran Segal and Dr. Eran Elinav from the Weizmann Institute, co-founders of DayTwo, and perform clinical trials to expand the current product to additional target populations, as well as to develop new products based on the microbiome. The company has completed a Series A round.